GlassScriptPhysician profile
Sarah D Merrick
NPI 1922134311
$1,963.53
in general payments reported to CMS, 2019-2025
19 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $165 · 2021: $526 · 2022: $396 · 2023: $381 · 2024: $208 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $629.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $306.11 | 2019-2024 | Fasenra, Farxiga, Breztri |
| Lilly USA, LLC | $268.34 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $188.01 | 2021-2024 | |
| Glaxosmithkline, LLC. | $129.94 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $108.97 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $49.17 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.01 | 2021-2022 | |
| Amarin Pharma, INC. | $40.54 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $26.86 | 2020-2021 | |
| Philips North America LLC | $21.21 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Endo Pharmaceuticals INC. | $19.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.49 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $12.20 | 2021 | |
| Shire North American Group INC | $11.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.29 | 2021 | |
| Eisai INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Merrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.